Asthma - Pipeline Review, H2 2015

Asthma - Pipeline Review, H2 2015

Code: GMDHC6821IDB | Published: Dec-2015 | Pages: 790 | Global Markets Direct
Price :

* Required Fields



Asthma - Pipeline Review, H2 2015


Global Markets Directs, Asthma - Pipeline Review, H2 2015, provides an overview of the Asthmas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Asthma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Asthma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Asthma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Asthma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
4D Pharma Plc
AB Science SA
Abeome Corporation
Accolade Pharma LLC
Acorda Therapeutics, Inc.
Adamis Pharmaceuticals Corporation
Advinus Therapeutics Ltd.
Afferent Pharmaceuticals, Inc.
Alba Therapeutics Corporation
ALK-Abello A/S
Allergopharma GmbH & Co. KG
Amakem NV
Amgen Inc.
AnaptysBio, Inc.
Antisense Therapeutics Limited
Aquinox Pharmaceuticals Inc.
ARA Healthcare Pvt. Ltd.
Ario Pharma Ltd
Array BioPharma Inc.
Aslan Pharmaceuticals Pte. Ltd.
Astellas Pharma Inc.
AstraZeneca Plc
Asubio Pharma Co., Ltd.
Aurigene Discovery Technologies Limited
Axikin Pharmaceuticals, Inc.
Basilea Pharmaceutica AG
Biokine Therapeutics Ltd.
BioLineRx, Ltd.
Bioncotech Therapeutics S.L.
Biotec Pharmacon ASA
BioTech Tools s.a.
Boehringer Ingelheim GmbH
Caladrius Biosciences, Inc.
CalciMedica, Inc.
Carolus Therapeutics, Inc.
Cellceutix Corporation
Cellular Biomedicine Group, Inc.
Celon Pharma Sp. z o.o.
Centrose LLC
Chiesi Farmaceutici SpA
Chong Kun Dang Pharmaceutical Corp.
Circassia Pharmaceuticals Plc
Cognosci, Inc.
CSL Limited
Cumberland Pharmaceuticals, Inc.
Cytokinetics, Inc.
Daiichi Sankyo Company, Limited
Dynavax Technologies Corporation
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
Foresee Pharmaceuticals, LLC
Fountain Biopharma Inc.
Genentech, Inc.
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
GliaCure Inc.
GlycoMar Limited
Griffin Discoveries BV
Han Wha Pharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
Histocell S.L.
Hydra Biosciences, Inc.
Hyundai Pharmaceutical Co., Ltd.
iCeutica, Inc.
iCo Therapeutics Inc.
Infinity Pharmaceuticals, Inc.
INOXIA Lifesciences GmbH
Invion Limited
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Johnson & Johnson
Kineta, Inc.
Kissei Pharmaceutical Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Kyowa Hakko Kirin Co., Ltd.
Laboratoires Pierre Fabre SA
Lead Discovery Center GmbH
LegoChem Biosciences, Inc
Ligand Pharmaceuticals, Inc.
Lpath, Inc.
Mabtech Limited
Marinomed Biotechnologie GmbH
MedImmune, LLC
Merck & Co., Inc.
Mitsubishi Tanabe Pharma Corporation
MSM Protein Technologies, Inc.
Mycenax Biotech Inc.
NAL Pharmaceuticals Ltd.
NeoPharm Co., Ltd.
Nostrum Pharmaceuticals, LLC
Novartis AG
Omeros Corporation
Ono Pharmaceutical Co., Ltd.
OPKO Health, Inc.
Orbis Biosciences, Inc.
Orion Oyj
Oxagen Limited
Palatin Technologies, Inc.
Panacea Biotec Limited
Panmira Pharmaceuticals, LLC.
Peptinnovate Limited
PharmaLundensis AB
Pharmaxis Limited
Plexxikon Inc.
Polyphor Ltd.
Portola Pharmaceuticals, Inc.
Progenra, Inc.
Promedior, Inc.
Protectimmun GmbH
Proteologics Ltd.
Pulmagen Therapeutics LLP
Qu Biologics Inc.
Re-Pharm Limited
Regeneron Pharmaceuticals, Inc.
Respiratorius AB
ReveraGen BioPharma, Inc.
Rhizen Pharmaceuticals S.A.
SK Chemicals Co., Ltd.
SkyePharma Plc
Spring Bank Pharmaceuticals, Inc.
Stallergenes S.A.
sterna biologicals Gmbh & Co KG
Sumitomo Dainippon Pharma Co., Ltd.
Sun Pharma Advanced Research Company Ltd.
Sunovion Pharmaceuticals Inc.
Swecure AB
Synovo GmbH
Syntrix Biosystems, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Limited
The International Biotechnology Center (IBC) Generium
Therabron Therapeutics, Inc.
Theraclone Sciences, Inc.
Theravance Biopharma, Inc.
Tolerys SA
Vectura Group Plc
Verona Pharma Plc
Visionary Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.
Xencor, Inc.
Yungjin Pharm. Co., Ltd.
Zambon Company S.p.A.
Ziarco Pharma Ltd

Report Format

Following are different modes of Licenses.

a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.

b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.

c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.

Quick Help

1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :

a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]

b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]

2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:

a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
d. Paypal

3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.

If you have a more question about our publications please see our FAQs section or contact us now at


There are no reports matching the selection.

Browse similar reports by category:
Pharmaceuticals & Healthcare
Global Markets Direct

Our Clients